Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical data.
Journal: Journal of the International AIDS Society
Published: August 10, 2024
Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral Therapy.
Journal: Open forum infectious diseases
Published: December 15, 2023
Preparing better: Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) therapeutics trials lessons learned: A call to the future.
Journal: Journal of clinical and translational science
Published: August 30, 2023
Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIV.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: April 30, 2021
Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 Study.
Journal: Journal of clinical pharmacology
Published: April 21, 2021
Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: January 14, 2021
Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption.
Journal: The Journal of clinical investigation
Published: May 28, 2019
Highlights from the Fourth Biennial Strategies for an HIV Cure Meeting, 10-12 October 2018, Bethesda, MD, USA.
Journal: Journal of virus eradication
Published: February 26, 2019
Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: January 24, 2019
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.
Journal: The lancet. HIV
Published: November 19, 2018
Last Updated: 09/26/2026